Neuraminidase Inhibitors Drug Market Analysis

Route of Administration Segment Analysis

In the route of administration segment, oral sub-segment dominates the segment and is forecasted to hold the market share of 53.1% by 2035. Oral dosage forms are used because of the ease of administration, reduced cost of delivery, and highly suitable for outpatient use. As per the NIH's NIAID Influenza Research Program report, oral neuraminidase inhibitors had the largest utilization during pandemic preparedness activities owing to logistical feasibility. Furthermore, oral avenues decrease the burden in the healthcare system by enhancing early intervention in the home or primary care. This pathway is particularly crucial for rural and low-resource areas where intravenous or inhalation avenues are not readily available.

Drug Class Segment Analysis

Under the drug class segment, oseltamivir dominates the market and is anticipated to hold the highest share by 2035. Oseltamivir is driven by its availability as an oral medication, well-established safety profile, and inclusion in government stockpiles. The CDC report in February in 2025 depicts that oseltamivir is FDA-approved for treating people affected by influenza A/B in ≥2 weeks and for prophylaxis in patients ≥1 year. The U.S. Strategic National Stockpile holds millions of oseltamivir treatment courses. Oseltamivir's efficacy during seasonal and pandemic influenza epidemics, as well as its inclusion in the WHO Model List of Essential Medicines, solidifies its position as the most trusted neuraminidase inhibitor. Its global availability and large-scale generic manufacturing ensure widespread adoption, mainly in middle-income nations.

End user Segment Analysis

In the end user segment, the hospitals and clinics lead the segment and are expected to drive the market by 2035. The hospitals and clinics are driven by the rising hospitalization rates due to a severe rise in influenza cases, mainly among the elderly population, people with chronic disease, and immunocompromised patients. According to the CDC report in September 2025, hospitalization cases related to influenza registered in the U.S. is 127.1 per 100,000 in the U.S. during the high flu season, highlighting the key role of inpatient care settings in the administration of antiviral care therapy. Further, hospitals are the key source for managing complications such as pneumonia and secondary infections, necessitating intravenous or antiviral therapies such as peramivir.

Our in-depth analysis of the neuraminidase inhibitors drug market includes the following segments: